Clinical Trial Update: Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU) [Phase 4]

View source ↗

Summary

A Phase 4 long-term safety and clinical outcomes study of LivmArli in patients with Alagille Syndrome in the European Union is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alagille Syndrome

Drugs mentioned

• LIVMARLI (Maralixibat chloride)

Snippet

Sponsor: Mirum Pharmaceuticals, Inc. | Conditions: Alagille Syndrome | Phase 4 | Status: RECRUITING